APGE
Apogee Therapeutics, Inc.
1W: +17.6%
1M: +10.2%
3M: +0.7%
YTD: +3.6%
1Y: +92.3%
$78.53
+5.53 (+7.58%)
After Hours: $79.25 (+0.72, +0.92%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$31.9M
Congress—
ETF Holdings—
Key Statistics
Market Cap$4.3B
52W Range26.2-85.04
Volume3,284,412
Avg Volume961,793
Beta1.40
Dividend—
Analyst Ratings
Company Info
CEOMichael Thomas Henderson
Employees196
SectorHealthcare
IndustryBiotechnology
IPO Date2023-07-14
Websiteapogeetherapeutics.com
221 Crescent Street
Waltham, MA 02453
US
Waltham, MA 02453
US
650-394-5230
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
Latest News
Apogee Therapeutics prices upsized $350M offering at $70 a share
Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering
APGE Stock Up as Skin Disease Drug Shows Sustained 52-Week Efficacy
Apogee Therapeutics announces $300 million public offering
Crude Oil Falls Sharply; Dell Shares Spike Higher
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| HENDERSON MICHAEL TH | S-Sale | 8,363 | $74.29 | 2026-03-11 |
| HENDERSON MICHAEL TH | S-Sale | 8,219 | $74.83 | 2026-03-11 |
| HENDERSON MICHAEL TH | S-Sale | 3,418 | $75.86 | 2026-03-11 |
| Dambkowski Carl | M-Exempt | 4,125 | $22.86 | 2026-03-04 |
| Dambkowski Carl | S-Sale | 3,225 | $70.33 | 2026-03-04 |